Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Prior treatment

• Has received prior treatment with a PRMT5 inhibitor, or MAT2A inhibitor
• Arms A and B only: Prior enrollment in any phase 3 clinical trial of RMC-6236 or RMC-9805
• Is currently participating in or has planned concurrent participation in a study of another investigational agent or device.

Other illness

• Known allergy, hypersensitivity or intolerance to TNG462 (all arms), RMC-6236 Arm A), RMC-9805 (Arm B), mFOLFIRINOX (Arm C), gemcitabine/nab-paclitaxel (Arm D) or their excipients
• Has uncontrolled intercurrent illness that will limit compliance with the study requirements.
• Has an active infection requiring systemic therapy.
• Has impairment of GI function or disease that may significantly alter the absorption of the oral medications
• Has current active liver disease from any cause
• Has clinically relevant cardiovascular disease
• History of or presence of active interstitial lung disease

Lab values

• Is known to be HIV positive, unless all the following criteria are met:
  • CD4+ count ≥300/µL.
  • Undetectable viral load.
  • Receiving highly active antiretroviral therapy
• Is unwilling or unable to comply with the scheduled visits, study treatment administration plan, laboratory tests or other study procedures and study restrictions.
• Has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion may affect the safety of the patient or impair the ability to assess study results

Other

• Has known or suspected active or untreated CNS metastases associated with progressive neurological symptoms
• Is a female patient who is pregnant or lactating

• Is ≥18 years of age at the time of signature of the main study ICF.
• Has an ECOG PS of 0 or 1.
• Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gene
• Arms A and B only: Has a tumor with a RAS mutation
• Pathologically documented metastatic PDAC or locally advanced, recurrent or metastatic NSCLC
• Has received prior standard therapy
• Arms A and B only: Must not have received prior RAS-targeted therapy
• Has evidence of measurable disease based on RECIST v1.1.
• Adequate organ function
• Must be able to swallow tablets.
• Negative pregnancy test at screening
• Written informed consent must be obtained according to local guidelines